Publications by authors named "S G SCHADE"
Article Synopsis
- A novel α-synuclein seed amplification assay (synSAA) was developed to differentiate misfolded α-synuclein seeds linked to multiple system atrophy (MSA) and Parkinson's disease (PD).
- The study analyzed cerebrospinal fluid (CSF) and brain samples from various clinical cohorts across multiple medical centers to assess the assay's diagnostic accuracy.
- Findings showed that brain samples with Lewy bodies were positive for synSAA, indicating potential for the assay in distinguishing between MSA and PD in diagnostic settings.
Background: Preferences for risk disclosure in population-based studies assessing Parkinson's disease (PD) risk have not been assessed so far.
Objectives: To examine preferences for risk disclosure in a subset of the European Healthy Brain Aging (HeBA) multicenter study.
Methods: After a remote PD risk assessment, a structured pilot-questionnaire on risk disclosure was first presented to participants (≥50 years, without neurodegenerative diseases) during in-person visits at the Innsbruck study site.
Background: Perinatal depression affects 10-15% of mothers and approximately 5% of fathers. However, only a small number of affected individuals seek treatment. If left unrecognized and untreated, it can have negative long-term consequences for the family's health, leading to subsequent high costs.
View Article and Find Full Text PDFParkinson's disease is increasingly prevalent. It progresses from the pre-motor stage (characterised by non-motor symptoms like REM sleep behaviour disorder), to the disabling motor stage. We need objective biomarkers for early/pre-motor disease stages to be able to intervene and slow the underlying neurodegenerative process.
View Article and Find Full Text PDF